Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.38 |
| ▸ | S1PR2 known ✓ | O95136 | 1/20 | 0.35 |
| ▸ | S1PR1 known ✓ | P21453 | 1/20 | 0.35 |
| ▸ | S1PR3 known ✓ | Q99500 | 1/20 | 0.35 |
| ▸ | S1PR5 known ✓ | Q9H228 | 1/20 | 0.35 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 2/20 | 0.33 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.33 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.31 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.48 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.48 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.48 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.48 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HBB | P68871 | 1/20 | 0.36 |
| ▸ | KDM4A | O75164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1231390 | 0.97 | PRMT3 (0.50) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL26929242 | 0.94 | PRMT3 (0.48) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL16317337 | 0.94 | PRMT3 (0.48) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL469832 | 0.94 | PRMT3 (0.48) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL10045279 | 0.94 | PRMT3 (0.48) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL19546063 | 0.92 | PRMT3 (0.46) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL11441189 | 0.92 | PRMT1 (0.52) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL14178222 | 0.89 | EPHX1 (0.48) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL25075475 | 0.88 | PRMT3 (0.48) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL2306167 | 0.87 | PRMT3 (0.55) | PRMT3CARM1PRMT6PRMT1PRMT8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078095-A1 | NEUROTENSIN RECEPTOR LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2026-03-19 | — | — | US | disclosed |
| EP-3712131-B1 | NEUROTENSIN RECEPTOR LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2023-02-01 | — | — | EP | disclosed |
| CN-109320502-B | Neurotensin receptor ligands | 3B制药有限公司 | 2022-06-07 | — | — | CN | disclosed |
| US-10961199-B2 | Neurotensin receptor ligands | 3B PHARMACEUTICALS GMBH (DE) | 2021-03-30 | — | — | US | disclosed |
| US-20210087149-A1 | NEUROTENSIN RECEPTOR LIGANDS | 3B Pharmaceuticals (DE) | 2021-03-25 | — | — | US | disclosed |
| US-10799605-B2 | Conjugate comprising a neurotensin receptor ligand and use thereof | 3B PHARMACEUTICALS GMBH (DE) | 2020-10-13 | — | — | US | disclosed |
| EP-3712131-A1 | NEUROTENSIN RECEPTOR LIGANDS | 3B Pharmaceuticals GmbH (DE) | 2020-09-23 | — | — | EP | disclosed |
| EP-2928870-B1 | NEUROTENSIN RECEPTOR LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2020-04-08 | — | — | EP | disclosed |
| CN-104837819-B9 | neurotensin receptor ligands | 3B制药有限公司 | 2019-07-09 | — | — | CN | disclosed |
| US-20170119913-A1 | CONJUGATE COMPRISING A NEUROTENSIN RECEPTOR LIGAND AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2017-05-04 | — | — | US | disclosed |
| EP-3154638-A1 | CONJUGATE COMPRISING A NEUROTENSIN RECEPTOR LIGAND AND USE THEREOF | 3B Pharmaceuticals GmbH (DE) | 2017-04-19 | — | — | EP | disclosed |
| WO-2015188934-A1 | CONJUGATE COMPRISING A NEUROTENSIN RECEPTOR LIGAND AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2015-12-17 | — | — | WO | disclosed |
| EP-2954933-A1 | Conjugate comprising a neurotensin receptor ligand | 3B Pharmaceuticals GmbH (DE) | 2015-12-16 | — | — | EP | disclosed |
| EP-2954934-A1 | Conjugate comprising a neurotensin receptor ligand and use thereof | 3B Pharmaceuticals GmbH (DE) | 2015-12-16 | — | — | EP | disclosed |
| US-20150299133-A1 | NEUROTENSIN RECEPTOR LIGANDS | 3 B Pharmaceuticals GmbH | 2015-10-22 | — | — | US | disclosed |
| EP-2928870-A1 | NEUROTENSIN RECEPTOR LIGANDS | 3B Pharmaceuticals GmbH (DE) | 2015-10-14 | — | — | EP | disclosed |
| WO-2014086499-A1 | NEUROTENSIN RECEPTOR LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2014-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087149-A1 | NEUROTENSIN RECEPTOR LIGANDS | NTSR1, NTSR2, TACR3 | CHRM2 89/4885S1PR2 590/4885S1PR1 461/4885 |
| US-20150299133-A1 | NEUROTENSIN RECEPTOR LIGANDS | NTSR1, NTSR2, TACR3 | CHRM2 85/4885S1PR2 584/4885S1PR1 453/4885 |
| US-20170119913-A1 | CONJUGATE COMPRISING A NEUROTENSIN RECEPTOR LIGAND AND USE THEREOF | NTSR1, NTSR2, ADGRF1 | CHRM2 40/4885S1PR2 688/4885S1PR1 507/4885 |
| US-10799605-B2 | Conjugate comprising a neurotensin receptor ligand and use thereof | NTSR1, NTSR2, TAAR1 | CHRM2 39/4885S1PR2 648/4885S1PR1 485/4885 |
| US-10961199-B2 | Neurotensin receptor ligands | NTSR1, NTSR2, TACR3 | CHRM2 85/4885S1PR2 584/4885S1PR1 453/4885 |
| US-20260078095-A1 | NEUROTENSIN RECEPTOR LIGANDS | NTSR1, NTSR2, GRPR | CHRM2 137/4885S1PR2 521/4885S1PR1 435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.